STOCK TITAN

Legend Biotech Corp - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.

Overview of Legend Biotech Corp

Legend Biotech Corp (NASDAQ: LEGN) is a clinical-stage biopharmaceutical company dedicated to harnessing cutting-edge cell therapy and CAR-T immunotherapy technologies to revolutionize the treatment of cancer, particularly multiple myeloma and other oncology indications. With a robust pipeline of chimeric antigen receptor (CAR) product candidates, the company leverages advanced scientific research and decades of expertise in molecular biology and immunology to address previously unmet medical needs in oncology.

Core Business and Strategic Focus

The core business of Legend Biotech revolves around the discovery, development, and clinical application of next-generation cell therapies. The company utilizes its proprietary platforms to develop CAR-T cell therapies that are designed to target and eliminate malignant cells in patients with liquid and solid tumors. By focusing on cancers that have long been considered incurable, such as multiple myeloma, Legend Biotech aims to improve treatment outcomes and extend patient survival. The company generates revenue through strategic licensing and collaboration agreements, partnering with established industry players to expand the reach of its innovative therapies.

Research, Development, and Innovation

Legend Biotech is recognized for its commitment to research and development. The company operates multiple R&D sites around the globe, ensuring a diverse and comprehensive approach to clinical research. Its teams of immunologists and molecular biologists work collaboratively to fine-tune CAR-T cell constructs and other cell-based therapies. This rigorous R&D approach has resulted in a strong pipeline of product candidates that undergo extensive clinical trials, with several therapies demonstrating promising efficacy in early and advanced stages of clinical evaluation.

Technology Platform and Pipeline

The company’s technology platform is built on the complex science of cellular engineering, enabling the development of both autologous and allogeneic cell therapies. These therapies often involve the genetic modification of a patient’s own immune cells to enhance their ability to recognize and kill cancer cells. A key product in its portfolio is a BCMA-targeted CAR-T cell therapy, which has shown significant clinical potential in treating relapsed or refractory multiple myeloma. This approach not only refines the patient’s immune response but also opens avenues for additional therapeutic applications across various oncologic disorders.

Market Position and Collaborative Strength

Within the competitive landscape of biopharmaceutical innovation, Legend Biotech positions itself as a vital contributor to the next generation of cancer treatment. The company’s involvement in high-profile clinical trials and its collaboration with major industry partners underscore its authoritative presence in the field. Its licensing and collaboration agreements with renowned organizations further reinforce its scientific credibility and operational robustness, positioning the company as an important player in global oncology research and treatment development.

Pipeline and Clinical Impact

Legend Biotech’s pipeline reflects its dedication to transforming cancer treatment paradigms. The company’s clinical trials have evaluated the safety and efficacy of its CAR-T therapies among diverse patient groups. These studies are designed to demonstrate not only impressive clinical responses but also enhancements in overall survival and quality of life among patients with challenging oncologic diagnoses. By rigorously testing its product candidates in multiple clinical settings, Legend Biotech contributes valuable data to the scientific community and paves the way for the broader adoption of cell therapies in routine clinical practice.

Scientific Rigor and Regulatory Engagement

Undergirding its product development is a strong commitment to scientific rigor and regulatory compliance. Legend Biotech adheres to strict quality standards in the development and manufacturing of its therapies, ensuring both efficacy and patient safety. Its active engagement with regulatory bodies worldwide reflects a proactive approach to meeting global standards, thereby enhancing the trust of both patients and healthcare providers in its therapies.

Commitment to Advancing Oncology Treatment

At its core, Legend Biotech is driven by the vision of overcoming the long-standing challenges in cancer treatment. By advancing the science of cell therapies, the company seeks to offer novel, potentially transformative treatments that redefine the standard of care in oncology. Its comprehensive approach, which integrates innovative research, deep scientific expertise, and strategic collaborations, enables Legend Biotech to contribute meaningfully to the evolving landscape of immunotherapy and personalized medicine.

Key Highlights

  • Innovative Cell Therapies: Focused on CAR-T cell therapies for addressing difficult-to-treat cancers, especially in the field of oncology.
  • Advanced R&D: Multiple research centers globally support expansive R&D efforts and clinical trials.
  • Collaborative Revenue Model: Strategic licensing and collaboration agreements enhance scientific advancement and market reach.
  • Clinical Expertise: Demonstrated capabilities in conducting rigorous clinical trials and generating actionable clinical data.
  • Regulatory Engagement: Active interactions with regulatory agencies ensure adherence to high quality and safety standards.

Conclusion

Legend Biotech Corp stands as a formidable entity in the field of biotechnology, focusing on the development of best-in-class immunotherapies. Through its innovative cell therapy platforms and robust clinical research programs, the company is committed to revolutionizing cancer treatment and improving patient outcomes in oncology. Its deep scientific expertise, combined with a strategic approach to R&D and global collaborations, solidifies its reputation as an authoritative and trustworthy source in the biopharmaceutical landscape.

Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced the submission of a New Drug Application (NDA) for its CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), to Japan's Ministry of Health. This submission is based on pivotal data from the CARTITUDE-1 study targeting adults with relapsed or refractory multiple myeloma. Cilta-cel has received several designations, including Breakthrough Therapy Designation. The ongoing international regulatory review underscores its potential to address significant treatment gaps for patients with limited options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
none
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) will host a hybrid event on Monday, December 13 at 8pm ET, featuring key opinion leaders in multiple myeloma. The meeting will present new data from the CARTITUDE Clinical Development Program focused on ciltacabtagene autoleucel (cilta-cel), an investigational CAR-T therapy for patients with relapsed/refractory multiple myeloma. This presentation follows the studies at the 63rd ASH Annual Meeting. Interested parties can access the event on the Legend Biotech website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
conferences
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has submitted a New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel) to the Japanese Ministry of Health, Labour and Welfare. This investigational CAR-T cell therapy targets B-cell maturation antigen (BCMA) for adults with relapsed or refractory multiple myeloma who have undergone at least three prior therapies. The NDA is based on the CARTITUDE-1 study results, and cilta-cel is under review by various global health authorities, including in the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
Rhea-AI Summary

The press release regarding LEGN has been deleted by the news provider, leaving no information available for analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary

Legend Biotech reported its Q3 2021 financial results, showcasing a revenue increase to $16.9 million, up from $11.7 million in Q3 2020. Key developments include the completion of enrollment in the Phase 3 CARTITUDE-4 study for cilta-cel in multiple myeloma and the initiation of a Phase 1 trial for LB1901 targeting T-cell lymphoma. Despite these advancements, the company faced a net loss of $124.8 million for the quarter. The FDA extended the cilta-cel PDUFA target date to February 28, 2022, allowing additional review time. Upcoming data presentations are scheduled for the ASH Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced the acceptance of 12 studies for presentation at the 63rd American Society of Hematology Annual Meeting. Highlights include data from the CARTITUDE-1 study, which focuses on cilta-cel for treating relapsed/refractory multiple myeloma, showcasing its efficacy in high-risk patients. The first data from CARTITUDE-2 will also be revealed, along with promising preclinical results for the tri-specific VHH CAR-T (LCAR-AIO) therapy targeting B-cell malignancies. Key presentations will occur from December 11-14, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
Rhea-AI Summary

Legend Biotech Corporation announced an extension of the Prescription Drug User Fee Act (PDUFA) target date for its investigational CAR-T therapy, ciltacabtagene autoleucel (cilta-cel), to February 28, 2022. This decision by the FDA was made to review updated analytical methods submitted by Janssen Biotech, with whom Legend collaborates. The CEO expressed confidence in cilta-cel's potential for patients with relapsed and refractory multiple myeloma. Notably, no additional clinical data have been requested by the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) will host its first Research & Development Day on October 18, starting at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue, New York. The event will showcase updates on their advancing pipeline for hematological and oncological indications, including their BCMA clinical development program. Presentations will be made by senior leaders, including CEO Ying Huang and CSO Frank Fan. A live webcast will be available on the Legend Biotech website, with recordings accessible for six months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
conferences
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has initiated a Phase 1 clinical trial for LB1901, an autologous CAR-T therapy targeting CD4 for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The trial follows FDA approval of the Investigational New Drug (IND) application and is led by Dr. Swaminathan P. Iyer at The University of Texas MD Anderson Cancer Center. This open-label, multi-center study aims to assess the safety and optimal dosing of LB1901 for patients with unmet medical needs in these serious conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced its participation in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 10. CEO and CFO Ying Huang will represent the company at 8:45 a.m. Eastern Time. Investors can access the conference webcast on the Legend Biotech website. The company focuses on developing novel cell therapies for oncology, notably its lead candidate cilta-cel for multiple myeloma, currently in registrational clinical trials. With over 900 employees across the U.S., China, and Europe, Legend Biotech is poised to advance innovative treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences

FAQ

What is the current stock price of Legend Biotech (LEGN)?

The current stock price of Legend Biotech (LEGN) is $32.01 as of April 4, 2025.

What is the market cap of Legend Biotech (LEGN)?

The market cap of Legend Biotech (LEGN) is approximately 5.8B.

What is Legend Biotech Corp's core focus?

Legend Biotech focuses on developing innovative cell therapies, especially CAR-T immunotherapy, to treat challenging cancers like multiple myeloma.

How does Legend Biotech generate revenue?

The company generates revenue through strategic licensing and collaboration agreements, leveraging its innovative product pipeline and research advancements.

What distinguishes Legend Biotech's CAR-T therapies?

Their CAR-T therapies are designed using proprietary cellular engineering techniques to enhance immune cell targeting of malignant cells, demonstrating promising efficacy in clinical trials.

In which clinical areas does Legend Biotech operate?

Legend Biotech primarily operates in oncology, developing cell therapies for both liquid and solid tumors, with a significant focus on multiple myeloma.

What is the importance of the company’s R&D efforts?

Their global R&D facilities and teams of experts ensure a rigorous approach to clinical development, fostering innovation and maintaining high standards in therapeutic research.

How is Legend Biotech positioned in the global market?

Through strategic collaborations and robust clinical trial data, Legend Biotech has established itself as a respected and influential player in advanced cell therapy and cancer treatment.

What types of therapies does Legend Biotech develop?

The company develops both autologous and allogeneic cell therapies, with a strong focus on CAR-T cell therapy aimed at treating various forms of cancer.

How does Legend Biotech ensure the safety and quality of its therapies?

The company adheres to stringent quality control and regulatory standards, actively engaging with global regulatory bodies to ensure its therapies meet the highest safety and efficacy benchmarks.
Legend Biotech Corp

Nasdaq:LEGN

LEGN Rankings

LEGN Stock Data

5.85B
181.20M
1.33%
55.49%
7.14%
Biotechnology
Healthcare
Link
United States
Somerset